US incentive scheme for neglected diseases: a good idea gone wrong?
PublisherBMJ Publishing Group
MetadataShow full item record
DescriptionThe US priority review voucher scheme was intended to encourage drug companies to invest in treatments for neglected diseases. But nearly seven years on, the author reports, there is little demonstrated innovation and evidence that the benefits are not going where they were intended.
CitationDoshi, P. (2014). US incentive scheme for neglected diseases: a good idea gone wrong? BMJ, 349. DOI: 10.1136/bmj.g4665
priority review vouchers
United States. Food and Drug Administration
Neglected Diseases--drug therapy
Identifier to cite or link to this itemhttp://hdl.handle.net/10713/6607
- Experience With the Priority Review Voucher Program for Drug Development.
- Authors: Kesselheim AS, Maggs LR, Sarpatwari A
- Issue date: 2015 Oct 27
- The economics of priority review vouchers.
- Authors: Dimitri N
- Issue date: 2010 Nov
- "Creating hope" and other incentives for drug development for children.
- Authors: Connor E, Cure P
- Issue date: 2011 Jan 19
- [Drugs for 'neglected diseases': a bitter pill].
- Authors: Veeken H, Pécoul B
- Issue date: 2000 Jun 24
- Developing drugs for developing countries.
- Authors: Ridley DB, Grabowski HG, Moe JL
- Issue date: 2006 Mar-Apr